WO1998036728A3 - Sustained analgesia achieved with buprenorphine - Google Patents

Sustained analgesia achieved with buprenorphine Download PDF

Info

Publication number
WO1998036728A3
WO1998036728A3 PCT/US1998/003584 US9803584W WO9836728A3 WO 1998036728 A3 WO1998036728 A3 WO 1998036728A3 US 9803584 W US9803584 W US 9803584W WO 9836728 A3 WO9836728 A3 WO 9836728A3
Authority
WO
WIPO (PCT)
Prior art keywords
buprenorphine
dosing interval
day
additional
manner indicative
Prior art date
Application number
PCT/US1998/003584
Other languages
French (fr)
Other versions
WO1998036728A9 (en
WO1998036728A2 (en
Inventor
Robert F Reder
Paul D Goldenheim
Original Assignee
Euro Celtique Sa
Robert F Reder
Paul D Goldenheim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26715643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998036728(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to NZ337386A priority Critical patent/NZ337386A/en
Priority to HU1200599A priority patent/HU230608B1/en
Priority to AU61841/98A priority patent/AU743071C/en
Priority to PL335306A priority patent/PL196086B1/en
Priority to CA002276170A priority patent/CA2276170C/en
Priority to KR1019997007713A priority patent/KR100703101B1/en
Priority to IL13156198A priority patent/IL131561A0/en
Application filed by Euro Celtique Sa, Robert F Reder, Paul D Goldenheim filed Critical Euro Celtique Sa
Priority to SI9830859T priority patent/SI0964677T1/en
Priority to JP10536980A priority patent/JP2000511936A/en
Priority to BR9815439-7A priority patent/BR9815439A/en
Priority to HU0002342A priority patent/HU230374B1/en
Priority to EP98906678A priority patent/EP0964677B1/en
Priority to DE69835584T priority patent/DE69835584T2/en
Publication of WO1998036728A2 publication Critical patent/WO1998036728A2/en
Publication of WO1998036728A3 publication Critical patent/WO1998036728A3/en
Publication of WO1998036728A9 publication Critical patent/WO1998036728A9/en
Priority to NO994087A priority patent/NO322515B1/en
Priority to IL131561A priority patent/IL131561A/en
Priority to AU2004218685A priority patent/AU2004218685B2/en
Priority to NO20064395A priority patent/NO329734B1/en
Priority to NO20074292A priority patent/NO329838B1/en
Priority to AU2008261134A priority patent/AU2008261134B2/en
Priority to IL201437A priority patent/IL201437A/en
Priority to IL207067A priority patent/IL207067A/en
Priority to NO20101190A priority patent/NO332248B1/en
Priority to IL214299A priority patent/IL214299A/en
Priority to NO20111441A priority patent/NO333374B1/en
Priority to NO20120563A priority patent/NO333139B1/en
Priority to NO20130298A priority patent/NO334290B1/en
Priority to NO20131533A priority patent/NO337094B1/en
Priority to NO20151450A priority patent/NO340067B1/en
Priority to NO2017011C priority patent/NO2017011I1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The use of buprenorphine in the preparation of a medicament for a method of effectively treating pain in humans is achieved by administering buprenorphine in a manner indicative of first order pharmacokinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in a manner indicative of zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
PCT/US1998/003584 1997-02-24 1998-02-24 Sustained analgesia achieved with buprenorphine WO1998036728A2 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
DE69835584T DE69835584T2 (en) 1997-02-24 1998-02-24 DELAYED ANALGESIS REACHES TRANSDERMAL ADMINISTRATION OF BUPRENORPHINE
JP10536980A JP2000511936A (en) 1997-02-24 1998-02-24 Sustained analgesia due to buprenorphine
SI9830859T SI0964677T1 (en) 1997-02-24 1998-02-24 Sustained analgesia achieved with transdermal delivery of buprenorphine
PL335306A PL196086B1 (en) 1997-02-24 1998-02-24 Prolonged anaesthetisation by means buprenophine
CA002276170A CA2276170C (en) 1997-02-24 1998-02-24 Sustained analgesia achieved with buprenorphine
KR1019997007713A KR100703101B1 (en) 1997-02-24 1998-02-24 Sustained analgesia achieved with buprenorphine
IL13156198A IL131561A0 (en) 1997-02-24 1998-02-24 The use of buprenorphine in the preparation of a medicament for treating pain
HU1200599A HU230608B1 (en) 1997-02-24 1998-02-24 Sustained analgesia achieved with buprenorphine
AU61841/98A AU743071C (en) 1997-02-24 1998-02-24 Sustained analgesia achieved with buprenorphine
NZ337386A NZ337386A (en) 1997-02-24 1998-02-24 Sustained analgesia achieved with buprenorphine via trans-dermal application
HU0002342A HU230374B1 (en) 1997-02-24 1998-02-24 Sustained analgesia achieved with buprenorphine
BR9815439-7A BR9815439A (en) 1997-02-24 1998-02-24 Continuous analgesia obtained with buprenorphine
EP98906678A EP0964677B1 (en) 1997-02-24 1998-02-24 Sustained analgesia achieved with transdermal delivery of buprenorphine
IL131561A IL131561A (en) 1997-02-24 1999-08-24 Use of buprenorphine in the preparation of a transdermal delivery sytem for treating pain
NO994087A NO322515B1 (en) 1997-02-24 1999-08-24 Use of buprenorphine in the preparation of a transdermal delivery system for the treatment of pain in a human patient
AU2004218685A AU2004218685B2 (en) 1997-02-24 2004-10-08 Method of providing sustained analgesia with buprenorphine
NO20064395A NO329734B1 (en) 1997-02-24 2006-09-28 Use of buprenorphine in the manufacture of a medicament
NO20074292A NO329838B1 (en) 1997-02-24 2007-08-22 Use of a polymer matrix layer which includes buprenorphine or a pharmaceutically acceptable salt thereof
AU2008261134A AU2008261134B2 (en) 1997-02-24 2008-12-19 Method of providing sustained analgesia with buprenorphine
IL201437A IL201437A (en) 1997-02-24 2009-10-11 Transdermal delivery systems of buprenorphine for use in treating pain
IL207067A IL207067A (en) 1997-02-24 2010-07-18 Transdermal delivery systems of buprenorphine for use in treating pain
NO20101190A NO332248B1 (en) 1997-02-24 2010-08-23 Transdermal delivery device and use of buprenorphine in the manufacture of a drug.
IL214299A IL214299A (en) 1997-02-24 2011-07-26 Transdermal delivery systems of buprenorphine for use in treating pain
NO20111441A NO333374B1 (en) 1997-02-24 2011-10-24 Transdermal delivery device comprising buprenorphine
NO20120563A NO333139B1 (en) 1997-02-24 2012-05-14 Transdermal delivery device comprising buprenorphine and use of buprenorphine in the manufacture of a medicament for the treatment of pain
NO20130298A NO334290B1 (en) 1997-02-24 2013-02-26 Transdermal delivery device containing buprenorphine for use in the treatment of pain and method of preparation thereof
NO20131533A NO337094B1 (en) 1997-02-24 2013-11-18 Use of buprenorphine in the preparation of a transdermal delivery system for the treatment of pain in a human patient
NO20151450A NO340067B1 (en) 1997-02-24 2015-10-26 Buprenorphine transdermal delivery device for use in pain management of a human patient
NO2017011C NO2017011I1 (en) 1997-02-24 2017-04-04 buprenorphine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3891997P 1997-02-24 1997-02-24
US60/038,919 1997-02-24
US08/939,068 US5968547A (en) 1997-02-24 1997-09-29 Method of providing sustained analgesia with buprenorphine
US08/939,068 1997-09-29

Publications (3)

Publication Number Publication Date
WO1998036728A2 WO1998036728A2 (en) 1998-08-27
WO1998036728A3 true WO1998036728A3 (en) 1998-12-10
WO1998036728A9 WO1998036728A9 (en) 1999-01-07

Family

ID=26715643

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/003584 WO1998036728A2 (en) 1997-02-24 1998-02-24 Sustained analgesia achieved with buprenorphine

Country Status (22)

Country Link
US (15) US5968547A (en)
EP (9) EP2305193A1 (en)
JP (1) JP2000511936A (en)
KR (1) KR100703101B1 (en)
CN (2) CN1252705A (en)
AT (3) ATE336212T1 (en)
AU (2) AU2004218685B2 (en)
BR (1) BR9815439A (en)
CA (1) CA2276170C (en)
CZ (2) CZ299414B6 (en)
DE (2) DE05011213T1 (en)
DK (4) DK2305194T3 (en)
ES (4) ES2271988T3 (en)
HK (3) HK1096847A1 (en)
HU (3) HU230608B1 (en)
IL (4) IL131561A0 (en)
NO (11) NO322515B1 (en)
NZ (1) NZ337386A (en)
PL (1) PL196086B1 (en)
PT (4) PT1570823E (en)
SI (3) SI0964677T1 (en)
WO (1) WO1998036728A2 (en)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265353A1 (en) * 1995-07-28 2004-12-30 Zars, Inc. Systems and methods for treating panic attacks
US20020114827A1 (en) * 1995-07-28 2002-08-22 Jie Zhang Methods and apparatus for improved administration of analgesics
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19746191C2 (en) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Method of using an active ingredient-containing patch to combat or alleviate addiction
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
RU2241458C2 (en) 1997-12-22 2004-12-10 Эро-Селтик, С.А. Combinations of agonist/antagonist for opioid
SE9803240D0 (en) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
JP2003522144A (en) 2000-02-08 2003-07-22 ユーロ−セルティーク，エス．エイ． Controlled release compositions comprising opioid agonists and antagonists
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1935421A1 (en) 2000-02-08 2008-06-25 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1280485A4 (en) * 2000-02-29 2006-11-29 Zars Inc Improved transdermal drug patch
KR100452972B1 (en) * 2000-05-16 2004-10-14 주식회사 삼양사 Hydrogel composition for transdermal drug
AU2001262683A1 (en) * 2000-06-02 2001-12-17 Teijin Limited Buprenorphine-containing patch
GB0021317D0 (en) * 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
ATE399551T1 (en) * 2000-10-23 2008-07-15 Euro Celtique Sa AIDS AND METHODS FOR THE TRANSDERMAL APPLICATION OF FELODIPINE
DE60141596D1 (en) 2000-10-23 2010-04-29 Euro Celtique Sa TRANSDERMALES SYSTEM FOR THE ADMINISTRATION OF LORATADINE AND ITS USE
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
JP4908726B2 (en) * 2001-02-16 2012-04-04 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング How to use buprenorphine to treat urinary incontinence
JP2004525960A (en) * 2001-02-16 2004-08-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Use of buprenorphine in the manufacture of transdermal delivery devices for the treatment of urinary incontinence, especially urge incontinence
BR0207978A (en) * 2001-03-02 2004-03-02 Euro Celtique Sa N-but-3enyl norbuprenorphine and methods of use
CN1525851A (en) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ Abuse-resistant controlled-release opioid dosage form
US7968119B2 (en) * 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
SI1416842T1 (en) 2001-07-18 2009-06-30 Euro Celtique Sa Pharmaceutical combinations of oxycodone and naloxone
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
ES2326794T3 (en) 2001-08-06 2009-10-20 Euro-Celtique S.A. FORMULATIONS OF OPIOID AGONISTS WITH LIBERABLE AND SEQUESTED ANTAGONISTS.
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7645813B2 (en) * 2001-08-10 2010-01-12 Cosmed Pharmaceutical Co., Ltd. Pressure-sensitive adhesive for the skin and tapes or sheets for the skin made by using the same
JP2005516926A (en) * 2001-12-17 2005-06-09 アリックス セラピューティクス Analgesic delivery system and method of use
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US20030181475A1 (en) * 2002-03-20 2003-09-25 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
ES2546010T3 (en) 2002-04-05 2015-09-17 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
WO2003101358A1 (en) * 2002-05-31 2003-12-11 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US20040033255A1 (en) 2002-06-10 2004-02-19 Baker Carl J. Transdermal delivery device disposal system
DE50307717D1 (en) * 2002-08-09 2007-08-30 Gruenenthal Gmbh OPIOD RECEPTOR ANTAGONISTS IN TRANSDERMAL SYSTEMS WITH BUPRENORPHINE
DE60326354D1 (en) * 2002-08-20 2009-04-09 Euro Celtique Sa TRANSDERMAL DOSAGE FORM CONTAINING AN ACTIVE SUBSTANCE AND AN ANTAGONIST IN FREE BASE AND SALT FORM
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
PT1551372T (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and metohds
EP1554290B1 (en) * 2002-10-25 2009-09-30 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
EP1913938A1 (en) 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
WO2004054554A1 (en) * 2002-12-13 2004-07-01 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
JP5054893B2 (en) * 2002-12-13 2012-10-24 ユーロ−セルティーク エス．エイ． Transdermal buprenorphine for analgesia
ZA200507877B (en) * 2003-03-31 2007-01-31 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US7879357B2 (en) * 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
EP2316440A1 (en) 2003-04-30 2011-05-04 Purdue Pharma L.P. Transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer and one fluid communication between the surface of the active agent and the adverse agent
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
WO2004103317A2 (en) * 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
NZ545505A (en) 2003-07-25 2010-02-26 Euro Celtique Sa Transdermal administration of buprenorphine for treatment of dependence withdrawal
UA81689C2 (en) * 2003-07-25 2008-01-25 Евро-Селтик С.А. Preoperative treatment of post operative pain with buprenorphine
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
DK2074989T3 (en) 2004-02-23 2014-02-03 Euro Celtique Sa ABUSE SAFETY TRANSDERMAL OPIOID DELIVERY DEVICE
US7220842B2 (en) * 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
HUE037643T2 (en) 2004-06-12 2018-09-28 Collegium Pharmaceutical Inc Abuse-deterrent drug formulations
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20060281775A1 (en) 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
EP1743638A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds
US8252329B2 (en) * 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9289583B2 (en) * 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
CN104138634B (en) * 2006-04-13 2016-09-07 梯瓦制药国际有限责任公司 The transdermal methods of delivery of anti-migraine compounds and system
PL2526932T3 (en) 2006-06-19 2017-12-29 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
DE102006054731B4 (en) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for administration of the active ingredient buprenorphine and use thereof in pain therapy
DE102006054732B4 (en) 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with ion-pair microreservoirs
US20110008431A1 (en) * 2007-04-02 2011-01-13 Toyo Boseki Kabushiki Kaisha Therapeutic tablet for postherpetic neuralgia and method of treating postherpetic neuralgia
JP5632284B2 (en) * 2007-08-07 2014-11-26 エーセルアールエックス ファーマシューティカルズ， インコーポレイテッド Compositions and methods for sedation and analgesia during treatment using oral transmucosal dosage forms
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2262367A4 (en) * 2008-03-08 2011-04-20 Theraquest Biosciences Inc Oral pharmaceutical compositions of buprenorphine and method of use
CN102056578A (en) * 2008-06-23 2011-05-11 生物递送科学国际公司 Multidirectional mucosal delivery devices and methods of use
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2010107761A1 (en) 2009-03-18 2010-09-23 Acelrx Pharmaceuticals, Inc. Improved storage and dispensing devices for administration of oral transmucosal dosage forms
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US20110037455A1 (en) * 2009-08-17 2011-02-17 Oren Navot System for measuring electrical power
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
DE102010024105A1 (en) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermal administration of memantine
DK2611445T3 (en) * 2010-09-03 2018-10-22 Zoetis Belgium S A HIGH DOSAGE-BUPRENORPHINE COMPOSITIONS AND USE AS ANALGETIC
WO2012048455A1 (en) * 2010-10-12 2012-04-19 武汉大学 Transdermal absorption patch of antiviral drug and its preparation method
CN103200944B (en) * 2010-11-17 2016-05-04 赫克萨尔股份公司 The Transcutaneous Therapeutic System that comprises buprenorphine
DE102011076653A1 (en) 2011-05-27 2012-11-29 Acino Ag Transdermal therapeutic system containing buprenorphine and an alpha hydroxy acid
WO2013042054A1 (en) * 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
MX352795B (en) * 2011-12-12 2017-12-07 Lts Lohmann Therapie Systeme Ag Transdermal delivery system comprising buprenorphine.
SG11201403075XA (en) * 2011-12-21 2014-07-30 Biodelivery Sciences Int Inc Transmucosal drug delivery devices for use in chronic pain relief
ES2663412T3 (en) * 2012-01-31 2018-04-12 Grünenthal GmbH Pharmaceutical patch for transdermal administration of (1R, 4R) -6'-fluor-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyran [3,4-b] indole] -4-amine
CN110101702A (en) 2012-04-17 2019-08-09 普渡制药公司 System and method for treating bad pharmacodynamics response caused by opioid
CN104736176B (en) * 2012-08-24 2017-10-13 英特格拉斯疗法有限公司 Chemical composition that and method for strengthening therapeutic agent transdermal delivery
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
JP6370802B2 (en) * 2012-12-28 2018-08-08 テイコク ファーマ ユーエスエー インコーポレーテッド Long-acting buprenorphine transdermal delivery composition and methods of use thereof
EA201592246A1 (en) 2013-06-04 2016-05-31 Лтс Лохманн Терапи-Системе Аг TRANSDERMAL DELIVERY SYSTEM
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
DE102014013448A1 (en) 2014-09-16 2016-03-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system comprising buprenorphine
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
SG11201704797TA (en) 2014-12-23 2017-07-28 Acelrx Pharmaceuticals Inc Systems, devices and methods for dispensing oral transmucosal dosage forms
US9656441B2 (en) 2015-01-08 2017-05-23 Alfred E. Tiefenbacher ( Gmbh & Co. Kg) Transdermal patch
JP6660399B2 (en) 2015-03-10 2020-03-11 ローズ テクノロジーズ Preparation of buprenorphine acetate and buprenorphine
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
JP2021517572A (en) * 2018-03-13 2021-07-26 エルテーエス ローマン テラピー−ジステーメ アーゲー Transdermal treatment system containing silicone acrylic hybrid polymer
US20210251983A1 (en) * 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Methods of treatment with buprenorphine
EP4238669A1 (en) 2022-03-02 2023-09-06 Recutech S.r.o. Method of manufacturing a heat-humidity exchange plate of an enthalpy air-to-air exchanger, a heat-humidity exchange plate and an enthalpy exchanger

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5132115A (en) * 1986-04-17 1992-07-21 Karin Wolter Planar therapeutic system, process for its production and utilization
US5225199A (en) * 1990-04-24 1993-07-06 Teijin Limited Pharmaceutical plasters
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4058599A (en) 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
US4262003A (en) * 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
US4060084A (en) * 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4119713A (en) 1977-02-09 1978-10-10 Sam Carosio Analgesic and anti-inflammatory composition
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
DE3330750A1 (en) * 1983-08-26 1985-03-14 Chemische Werke Hüls AG, 4370 Marl METHOD FOR GENERATING ACETYLENE AND SYNTHESIS OR REDUCING GAS FROM COAL IN AN ARC PROCESS
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4636539A (en) 1984-01-30 1987-01-13 Loctite (Ireland) Limited Instant adhesive composition utilizing calixarene accelerators
US4601893A (en) 1984-02-08 1986-07-22 Pfizer Inc. Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
DE3546830C2 (en) 1984-07-23 1995-07-20 Alza Corp Device for delivering fentanyl across the skin
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4834978A (en) 1984-10-01 1989-05-30 Biotek, Inc. Method of transdermal drug delivery
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4698062A (en) 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
USRE33093E (en) 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
JPS62298530A (en) 1986-06-16 1987-12-25 Otsuka Pharmaceut Co Ltd Pharmaceutical composition for suppository
US4938759A (en) 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5091405A (en) * 1987-01-05 1992-02-25 E. I. Du Pont De Nemours And Company Insecticidal pyrazolines
US5171576A (en) 1987-03-09 1992-12-15 Alza Corporation Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
DE3812481A1 (en) * 1987-08-26 1989-03-09 Bayer Ag WATERPROOF POLYMER PREPARATION
US4915954A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4983395A (en) * 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4994278A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Breathable backing
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
US5336210A (en) * 1989-02-28 1994-08-09 Teijin Limited Plaster agent
US5028435A (en) 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
DE3939376C1 (en) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
EP0432945A1 (en) 1989-12-12 1991-06-19 Warner-Lambert Company A transdermal delivery system for treatment of cocaine and heroin addiction
JP2849937B2 (en) * 1990-04-18 1999-01-27 日東電工株式会社 Medical patch
DE4020144A1 (en) * 1990-06-25 1992-01-09 Lohmann Therapie Syst Lts Patches for topical or transdermal drug delivery - with adhesive layer contg. polyacrylate adhesive and film former
US5688547A (en) 1990-08-03 1997-11-18 American Cyanamid Company Meal replacement composition and method of weight control
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
CN1036343C (en) 1990-11-10 1997-11-05 天津市计划生育研究所 Synthesis, products and its application for luleinizing hormone releasing hormone and antagonistic znalogue
PL166095B1 (en) 1991-04-03 1995-03-31 Warszawskie Zaklady Farma Method of obtaining buprenophine
CA2102507A1 (en) 1991-05-07 1992-11-08 Judith P. Kitchell A controlled, sustained release delivery system for smoking cessation
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5225440A (en) * 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
US5229130A (en) 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5272149A (en) 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
WO1993023019A1 (en) 1992-05-11 1993-11-25 Sri International Transdermal drug delivery systems and related compositions and methods of use
WO1993023025A1 (en) 1992-05-13 1993-11-25 Alza Corporation Transdermal administration of oxybutynin
DK0644746T3 (en) 1992-06-11 1999-12-20 Theratech Inc Use of glycerine to moderate transdermal drug delivery
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
DE4237453C1 (en) 1992-11-06 1993-08-19 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
DE4301783C1 (en) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermal system per admin. of galanthamine - esp. for treatment of Alzheimer's disease and alcohol addiction
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
ES2115231T3 (en) * 1993-04-20 1998-06-16 Hexal Ag PLASTER WITH ACTIVE SUBSTANCES.
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
JPH08512054A (en) 1993-06-25 1996-12-17 アルザ・コーポレーション Inclusion of poly-N-vinylamide in transdermal system
AU7566994A (en) 1993-08-16 1995-03-14 Cygnus Therapeutic Systems Contact adhesive extends wear time on skin
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
BR9506557A (en) 1994-01-20 1997-10-28 Akzo Nobel Nv Pharmaceutical composition and process to induce follicular growth and maturation in female individuals
JPH07206710A (en) * 1994-01-21 1995-08-08 Nitto Denko Corp Tape preparation for transcutaneous administration
PE44995A1 (en) 1994-01-27 1995-12-18 Schering Corp MOMETASONE FUROATE FOR THE TREATMENT OF LUNG DISEASES AND RESPIRATORY TRACT
JP2819236B2 (en) * 1994-05-06 1998-10-30 日東電工株式会社 Transdermal formulation
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5468457A (en) 1994-12-22 1995-11-21 Osram Sylvania Inc. Method of making tungsten-copper composite oxides
DE4446600A1 (en) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermal absorption of active ingredients from supercooled melts
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
WO1997004835A1 (en) * 1995-07-28 1997-02-13 Novartis Ag Transdermal system
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
FR2739731B1 (en) 1995-10-09 1998-01-02 Axon Cable Sa METHOD FOR CONNECTING COAXIAL MICRO-CABLES TO THE TRACKS OF A PRINTED CIRCUIT
DE19642043A1 (en) * 1995-10-23 1997-04-24 Hexal Ag Transdermal therapeutic system for treating drug dependency
US5792740A (en) 1996-03-08 1998-08-11 Firmenich Sa Fragrant macrocyclic lactones
WO1997035564A1 (en) 1996-03-25 1997-10-02 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system with small application-area thickness and great flexibility, and production process
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
US6271240B1 (en) 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
SE9602442D0 (en) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
JPH1036265A (en) 1996-07-19 1998-02-10 Nitto Denko Corp Buprenorphine percutaneous absorption preparation
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
EP0821957A3 (en) 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
US20010006677A1 (en) 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
AT405158B (en) * 1996-12-04 1999-06-25 Steyr Daimler Puch Ag METHOD FOR AUTOMATICALLY CONTROLLING THE LOCKING CLUTCHES OF AN ALL-WHEEL DRIVE VEHICLE AND VEHICLE WITH ARTICULATED STEERING AND LOCKABLE DIFFERENTIALS
US6787149B1 (en) 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
DE19652188C2 (en) 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flat drug preparation for application and release of buprenorphine or a pharmacologically comparable substance in the oral cavity and process for its preparation
EP0998289A1 (en) 1997-02-07 2000-05-10 TheraTech, Inc. Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
AU7273898A (en) 1997-04-30 1998-11-24 Human Pheromone Sciences, Inc. Method of fixing fragrances in fragrance composition and other compositions
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US5900420A (en) 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
GB2328443B (en) 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
DE19738855C2 (en) 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermal therapeutic system with adhesive reservoir layer and unidirectional elastic back layer
RS49982B (en) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
US7011843B2 (en) 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
DE19746191C2 (en) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Method of using an active ingredient-containing patch to combat or alleviate addiction
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
CN1204890C (en) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 Method for preventing abuse of opioid dosage forms
AU2981099A (en) 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
EP1064035B1 (en) 1998-03-23 2003-11-26 ELAN CORPORATION, Plc Drug delivery device
AU746339B2 (en) 1998-04-29 2002-04-18 Arius Two, Inc. Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
DE19840758A1 (en) 1998-09-07 2000-03-09 Liedtke Pharmed Gmbh Treatment of pain or depression comprises systemic administration of oxytocin
KR100383252B1 (en) 1998-12-17 2003-07-16 주식회사 삼양사 Transdermal Dosage Compositions Containing Buprenoline and Patches Comprising the Same
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
IT1305303B1 (en) 1999-03-10 2001-05-04 Farmigea Spa USE OF NIAOULI ESSENTIAL OIL AS A PROMOTER FOR TRANSDERMAL PERMEAZION.
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6554851B1 (en) 1999-05-07 2003-04-29 Scimed Life Systems, Inc. Methods of sealing an injection site
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (en) * 2000-02-25 2011-03-30 帝三製薬株式会社 Patch containing buprenorphine hydrochloride
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
SI1315502T1 (en) 2000-08-30 2010-07-30 Unimed Pharmaceuticals Llc Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
BR0207978A (en) 2001-03-02 2004-03-02 Euro Celtique Sa N-but-3enyl norbuprenorphine and methods of use
DE60236496D1 (en) 2001-03-23 2010-07-08 Einstein Coll Med METHOD FOR INCREASING THE ANALGETIC EFFECT AND REDUCING THE UNWANTED EXITATORY EFFECTS OF BIMODALALLY EFFECTIVE OPIOIDAGONISTS BY THE INHIBITION OF GM1 GANGLIOSIDE
EP1424973B1 (en) * 2001-04-23 2010-03-03 Euro-Celtique S.A. Disposal system for transdermal dosage form
ATE533478T1 (en) * 2001-05-01 2011-12-15 Euro Celtique Sa ABUSE-PROOF OPIOIDS WITH TRANSDERMAL SYSTEMS
EP1390866B1 (en) 2001-05-22 2010-01-20 Euro-Celtique S.A. Container and method for dispensing transdermal dosage forms
CA2449358A1 (en) 2001-06-04 2002-12-12 Qinetiq Limited Patterning method
WO2003009805A2 (en) 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
US20030114475A1 (en) 2001-10-31 2003-06-19 Addiction Therapies, Inc. Methods for the treatment of addiction
US20030181475A1 (en) 2002-03-20 2003-09-25 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
ATE382050T1 (en) 2002-11-25 2008-01-15 Chi Mei Foundation Medical Ct BUPRENORPHINE ESTER DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND LONG-ACTING ANALGESIC DRUGS
JP5054893B2 (en) 2002-12-13 2012-10-24 ユーロ−セルティーク エス．エイ． Transdermal buprenorphine for analgesia
WO2004054554A1 (en) * 2002-12-13 2004-07-01 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
WO2004103317A2 (en) 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
NZ545505A (en) * 2003-07-25 2010-02-26 Euro Celtique Sa Transdermal administration of buprenorphine for treatment of dependence withdrawal
UA81689C2 (en) 2003-07-25 2008-01-25 Евро-Селтик С.А. Preoperative treatment of post operative pain with buprenorphine
WO2005018565A2 (en) 2003-08-21 2005-03-03 Transoral Pharmaceuticals, Inc. Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
JP2008539729A (en) 2005-05-03 2008-11-20 イノゼン・インコーポレイテッド Edible film for transmucosal delivery of dietary supplements
BRPI0619806A2 (en) 2005-12-13 2011-10-18 Biodelivery Sciences Int Inc abuse resistant transmucosal drug delivery device
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
ES2376396T3 (en) 2006-06-26 2012-03-13 Amgen Inc. METHOD TO TREAT ATEROSCLEROSIS.
BRPI0714712B8 (en) 2006-07-21 2021-05-25 Biodelivery Sciences Int Inc drug delivery device
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
CN105168186A (en) 2006-10-02 2015-12-23 Apr应用制药研究股份公司 Non-mucoadhesive film dosage forms
AU2007305166A1 (en) 2006-10-03 2008-04-10 University Of Southern California GRP78 as a predictor of responsiveness to therapeutic agents
GB2447016A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
US20080226702A1 (en) 2007-03-16 2008-09-18 Endo Pharmaceuticals, Inc. Transdermal Delivery Form Disposal Systems and Methods
CN102056578A (en) 2008-06-23 2011-05-11 生物递送科学国际公司 Multidirectional mucosal delivery devices and methods of use
CN103200944B (en) 2010-11-17 2016-05-04 赫克萨尔股份公司 The Transcutaneous Therapeutic System that comprises buprenorphine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132115A (en) * 1986-04-17 1992-07-21 Karin Wolter Planar therapeutic system, process for its production and utilization
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5225199A (en) * 1990-04-24 1993-07-06 Teijin Limited Pharmaceutical plasters
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency

Also Published As

Publication number Publication date
US9642850B2 (en) 2017-05-09
ATE336212T1 (en) 2006-09-15
EP2305194B1 (en) 2012-05-09
HU230608B1 (en) 2017-03-28
EP1731152A3 (en) 2007-11-14
IL201437A (en) 2010-12-30
EP1570823B1 (en) 2011-12-28
NO20074292L (en) 1999-10-22
EP2305191A1 (en) 2011-04-06
KR100703101B1 (en) 2007-04-06
US20170056393A1 (en) 2017-03-02
KR20000075648A (en) 2000-12-26
ES2271988T3 (en) 2007-04-16
JP2000511936A (en) 2000-09-12
EP1570823A3 (en) 2006-01-18
US20150157625A1 (en) 2015-06-11
HK1096847A1 (en) 2007-06-15
EP0964677A1 (en) 1999-12-22
HU230374B1 (en) 2016-03-29
CA2276170C (en) 2007-12-04
PL335306A1 (en) 2000-04-10
EP1570823A2 (en) 2005-09-07
NO994087L (en) 1999-10-22
EP2305193A1 (en) 2011-04-06
USRE41571E1 (en) 2010-08-24
NO333139B1 (en) 2013-03-11
EP2301494A1 (en) 2011-03-30
IL131561A (en) 2010-05-31
EP2305192A1 (en) 2011-04-06
CZ299414B6 (en) 2008-07-16
BR9815439A (en) 2001-10-16
US20030198675A1 (en) 2003-10-23
AU2925402A (en) 2002-05-16
EP2305194A1 (en) 2011-04-06
ES2380023T3 (en) 2012-05-07
SI1570823T1 (en) 2012-03-30
USRE41408E1 (en) 2010-06-29
DE69835584D1 (en) 2006-09-28
US6231886B1 (en) 2001-05-15
NZ337386A (en) 2001-06-29
US5968547A (en) 1999-10-19
HUP0002342A3 (en) 2001-04-28
DK0964677T3 (en) 2006-12-11
HK1103621A1 (en) 2007-12-28
AU2008261134A1 (en) 2009-01-15
US20140073663A1 (en) 2014-03-13
NO337094B1 (en) 2016-01-18
NO329838B1 (en) 2011-01-10
CZ2015477A3 (en) 2015-10-21
PT964677E (en) 2006-12-29
NO322515B1 (en) 2006-10-16
HUP1500370D0 (en) 2000-12-28
IL131561A0 (en) 2001-01-28
AU774779B2 (en) 2004-07-08
NO20120563L (en) 1999-10-22
USRE41489E1 (en) 2010-08-10
AU743071B2 (en) 2002-01-17
CA2276170A1 (en) 1998-08-27
NO334290B1 (en) 2014-01-27
NO333374B1 (en) 2013-05-13
HUP0002342A2 (en) 2000-12-28
SI0964677T1 (en) 2006-12-31
EP1731152A2 (en) 2006-12-13
DK1570823T3 (en) 2012-02-20
US20130197020A1 (en) 2013-08-01
ATE556682T1 (en) 2012-05-15
CZ300999A3 (en) 2000-03-15
PT1570823E (en) 2012-03-02
NO20101190L (en) 1999-10-22
EP1731152B1 (en) 2013-05-01
PT1731152E (en) 2013-07-31
US20010002259A1 (en) 2001-05-31
IL207067A (en) 2011-12-29
AU6184198A (en) 1998-09-09
US20060216340A1 (en) 2006-09-28
DE05011213T1 (en) 2007-09-06
US20110288112A1 (en) 2011-11-24
AU2004218685B2 (en) 2009-01-22
NO20131533L (en) 1999-10-22
DE69835584T2 (en) 2007-08-16
US6344212B2 (en) 2002-02-05
NO2017011I1 (en) 2017-04-04
AU2004218685A1 (en) 2004-11-04
ES2387752T3 (en) 2012-10-01
AU2008261134B2 (en) 2012-08-02
US20030091631A1 (en) 2003-05-15
NO329734B1 (en) 2010-12-13
NO20064395L (en) 1999-10-22
ATE538765T1 (en) 2012-01-15
SI2305194T1 (en) 2012-10-30
CN1827107A (en) 2006-09-06
US20160220559A1 (en) 2016-08-04
DK2305194T3 (en) 2012-08-13
DK1731152T3 (en) 2013-07-22
ES2423925T3 (en) 2013-09-25
NO2016013I1 (en) 2016-07-18
EP0964677A4 (en) 2002-12-18
HUP1200599A2 (en) 2000-12-28
HK1153377A1 (en) 2012-03-30
NO20130298L (en) 1999-10-22
NO20151450A1 (en) 1999-10-22
NO20111441L (en) 1999-10-22
NO994087D0 (en) 1999-08-24
EP0964677B1 (en) 2006-08-16
PL196086B1 (en) 2007-12-31
PT2305194E (en) 2012-08-14
NO332248B1 (en) 2012-08-06
WO1998036728A2 (en) 1998-08-27
CN1252705A (en) 2000-05-10
CN1827107B (en) 2010-05-26
EP2301493A1 (en) 2011-03-30
NO340067B1 (en) 2017-03-06

Similar Documents

Publication Publication Date Title
WO1998036728A3 (en) Sustained analgesia achieved with buprenorphine
PL312587A1 (en) Method of treating pain by administration of 24-hour oral opioid preparations causing a quick initial increase of a drug concentration in plasma
GB2316004B (en) Novel formulations for transdermal delivery of pergolide
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
AUPN603895A0 (en) Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
HUP0300218A2 (en) Process for treatment of diabetes, employing combination of metformin and glyburide
PL338982A1 (en) Drug for improving duration of muscle action or for treating muscular disorders or diseases
HUP9801591A3 (en) Use of nitric oxide-releasing agents for producing pharmaceutical composition to treat impotency, and delivery device dosage of nitric oxide
CA2264852A1 (en) Use of methylphenidate or a pharmaceutically acceptable salt thereof
HK1084862A1 (en) Use of omega interferon in the manufacturing of a medicament for treating viral disease in a warm-blooded animal subject
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
YU48559B (en) Pharmaceutical formulation for treating nicotine addiction
WO2000004894A3 (en) Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
EP1201246A3 (en) Use of Thrombopoietin as a medicament for the therapy and prevention of thrombocytopenia
WO2005011579A3 (en) Treatment of dependence withdrawal
CA2108330A1 (en) Enhancer for the Antianemia Effect of Erythropoietin and Method of Augmenting the Antianemia Effect of Erythropoietin
James DOXIL approved for KS
EP0799618A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer
EP1197227A4 (en) Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method
WO1996020702B1 (en) The use of 2,3-alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndrome
Spiga et al. Effects of Pre-treatment of Diazepam on Methadone Self-Administration
AU1305999A (en) (+)-ephedrine as a sympathomimetic drug
WO2001039760A3 (en) Method of treating batten disease
UA10279A (en) Method for treating infantile cerebral paralysis
RO102780B1 (en) General anaesthesia method

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 131561

Country of ref document: IL

Ref document number: 98804261.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2276170

Country of ref document: CA

Ref document number: 2276170

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998906678

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1998 536980

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/007798

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV1999-3009

Country of ref document: CZ

Ref document number: 337386

Country of ref document: NZ

Ref document number: 1019997007713

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 61841/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998906678

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1999-3009

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997007713

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 61841/98

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1019997007713

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1998906678

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2008-19

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 201437

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 207067

Country of ref document: IL